Kraig Biocraft Laboratories to Open New Biotechnology Research and Production Center

ANN ARBOR, Mich., Oct. 02, 2017 -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced the Company is opening its new research and production headquarters in Michigan.  This facility will unite the Company’s ongoing recombinant spider silk production operations with its accelerating research into the creation of ever more powerful spider silk protein technologies. 

Over the next 30 days, the Company will be relocating its current production operations, from Indiana into its new larger facility, and will transfer key production staff, to ensure continuity of operations.  This new facility offers better environmental control, roughly three times the production space, significantly reduces overhead costs, and, for the first time in the Company’s history, will allow the Company’s research and production teams to work side by side producing today’s spider silk based products, and creating tomorrow’s possibilities.

The Company created two new lead positions within its research group to support the new facility and growing research efforts.  Individuals with strong laboratory experience working in genetic engineered, and interested in taking a lead role in a fast paced, growing Biotechnology Company, are encouraged to apply at https://tinyurl.com/ya43k5u7.

“Launching this new larger factory unifies our production and research teams’ efforts.  Having our teams working hand in hand will make us more agile and open up opportunities to move technologies more quickly from the drawing board to tested and validated designs,” said COO Jon Rice.  “In addition to streamlining developmental timelines and enhancing our ability to tailor fibers, we expect to reduce R&D costs, as we generate new spider silk technologies by fully integrating design, creation, testing, and scale up, under a single roof.  Our plan is to have this facility be the global central hub for spider silk technology and the center of our international operations.”

The Company’s domestic operations complement its ongoing work establishing international production centers.  Company management is currently considering three overseas locations for production.  Management is scheduled for meeting with senior central government officials in Hanoi, Vietnam in early October and is in ongoing discussions with another country silk producing country which has expressed interest in working with the Company to scale its spider silk technology.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.kraiglabs.com/newsletter

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
[email protected]